Format

Send to

Choose Destination
Onco Targets Ther. 2014 Aug 21;7:1481-5. doi: 10.2147/OTT.S65548. eCollection 2014.

miR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer.

Author information

1
Department of Pathology, Stony Brook Medicine, Stony Brook University, Stony Brook, NY, USA.

Abstract

In the last decade, cancer research efforts in the field of noncoding microRNA (miRNA) have been growing exponentially. miRNA-based therapeutics have been tested in both preclinical and clinical settings, and miRNA-based cancer diagnostics and prognostics have moved into clinics to help better manage cancer treatment. A growing body of evidence in recent literature suggests miRNA-129 plays important roles in gastrointestinal cancer, including gastric, colorectal, hepatocellular carcinoma, and esophageal cancer. In this review, we focus on accumulating evidence demonstrating the key roles that miRNA-129 plays in tumorigenesis, disease progression, chemoresistance, proliferation, and cell cycle control. Understanding the emerging roles and mechanisms of miRNA-129 in cancer will help us realize the therapeutic and diagnostic/prognostic potential.

KEYWORDS:

5-FU; biomarker; cancer; miR-129; therapeutics

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center